Download PDF
Semin Thromb Hemost 2006; 32(6): 605-615
DOI: 10.1055/s-2006-949665
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Women and von Willebrand Disease: Controversies in Diagnosis and Management

Rezan A. Kadir1 , 3 , Claudia Chi2 , 3
  • 1Consultant Obstetrician and Gynaecologist, Royal Free Hospital, London, United Kingdom
  • 2Clinical Research Fellow, Royal Free Hospital, London, United Kingdom
  • 3Department of Obstetrics and Gynaecology, the Royal Free Hospital, London, United Kingdom
Further Information

Publication History

Publication Date:
15 September 2006 (online)

    Permissions and Reprints

ABSTRACT

von Willebrand disease (vWD) is the commonest bleeding disorder in women. More than 70% of women with vWD suffer from menorrhagia and half of them suffer from dysmenorrhea. There is also the risk of hemorrhage with ovulation and mid-cycle pain. These have a significant effect on all aspects of quality of life. vWD also can be the underlying cause of menorrhagia in a small but significant proportion of women. There are still several unanswered issues in the diagnosis and management of menorrhagia in these women. There is no consensus whether testing for vWD should be part of the routine investigations in menorrhagia. Diagnosis of vWD is difficult. There are intraindividual variations in von Willebrand factor and factor VIII levels influenced by age, race, and blood group. This is further complicated in women because of the fluctuation of these factor levels during the menstrual cycle and possibly with hormonal therapy. The diagnosis of menorrhagia is also difficult due to the lack of a simple objective tool for the assessment of menstrual blood loss. In vWD, the treatment of menorrhagia is usually medical, but there is lack of prospective data on the efficacy of commonly used medical therapies in these women. The levonorgestrel intrauterine system, Mirena, is effective and should be considered prior to surgical management. Surgical interventions may be required in patients unresponsive to medical treatments. These procedures can be complicated by hemorrhage in these women. A multidisciplinary approach in the management of these women is essential in ensuring an optimal outcome. Multicenter clinical trials are required to answer the controversial issues in the management of women with vWD.

KEYWORDS

von Willebrand disease - women - menorrhagia - management - diagnosis

REFERENCES

  • 1 Federici A B, Mannucci P M. Actual management of von Willebrand disease: first report on 880 cases of the Italian registry of VWD.  Blood. 1997;  90 33a , (abst)
    PubMedGoogle Scholar
  • 2 Foster P A. The reproductive health of women with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.  Thromb Haemost. 1995;  74 784-790
    PubMedGoogle Scholar
  • 3 Ragni M V, Bontempo F A, Hassett A C. von Willebrand disease and bleeding in women.  Haemophilia. 1999;  5 313-317
    CrossrefPubMedGoogle Scholar
  • 4 Kadir R A, Economides D L, Sabin C A, Pollard D, Lee C A. Assessment of menstrual blood loss and gynaecological problems in patients with inherited bleeding disorders.  Haemophilia. 1999;  5 40-48
    CrossrefPubMedGoogle Scholar
  • 5 Kouides P A, Phatak P D, Burkart P et al.. Gynaecological and obstetrical morbidity in women with type I von Willebrand disease: results of a patient survey.  Haemophilia. 2000;  6 643-648
    CrossrefPubMedGoogle Scholar
  • 6 Rozeik C, Scharrer I. Gynecological disorders and psychological problems in 184 women with von Willebrand disease.  Haemophilia. 1998;  4 293
    CrossrefPubMedGoogle Scholar
  • 7 Kirtava A, Drews C, Lally C, Dilley A, Evatt B. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand's disease receiving care in haemophilia treatment centres: a case-control study.  Haemophilia. 2003;  9 292-297
    CrossrefPubMedGoogle Scholar
  • 8 James A H. More than menorrhagia: a review of the obstetric and gynaecological manifestations of bleeding disorders.  Haemophilia. 2005;  11 295-307
    CrossrefPubMedGoogle Scholar
  • 9 Barr R D, Sek J, Horsman J et al.. Health status and health-related quality of life associated with von Willebrand disease.  Am J Hematol. 2003;  73 108-114
    CrossrefPubMedGoogle Scholar
  • 10 Barr R D, Saleh M, Furlong W et al.. Health status and health-related quality of life associated with hemophilia.  Am J Hematol. 2002;  71 152-160
    CrossrefPubMedGoogle Scholar
  • 11 Whitton A C, Rhydderch H, Furlong W, Feeny D, Barr R D. Self-reported comprehensive health status of adult brain tumor patients using the Health Utilities Index.  Cancer. 1997;  80 258-265
    CrossrefPubMedGoogle Scholar
  • 12 Kadir R A, Sabin C, Pollard D, Lee C, Economides D L. Quality of life during menstruation in patients with inherited bleeding disorders.  Haemophilia. 1998;  4 836-841
    CrossrefPubMedGoogle Scholar
  • 13 Bruner A B, Joffe A, Duggan A K, Casella I F, Brandt J. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls.  Lancet. 1996;  348 992-996
    CrossrefPubMedGoogle Scholar
  • 14 Patterson A J, Brown W J, Roberts D CK. Dietary and supplement treatment of iron deficiency results in improvements in general health and fatigue in Australian women of childbearing age.  J Am Coll Nutr. 2001;  20 337-342
    PubMedGoogle Scholar
  • 15 Shankar M, Lee C A, Sabin C A, Economides D L, Kadir R A. von Willebrand disease in women with menorrhagia: a systematic review.  BJOG. 2004;  111 734-740
    CrossrefPubMedGoogle Scholar
  • 16 James A, Matchar D B, Myers E R. Testing for von Willebrand disease in women with menorrhagia: a systematic review.  Obstet Gynecol. 2004;  104 381-388
    PubMedGoogle Scholar
  • 17 Philipp C S, Faiz A, Dowling N et al.. Age and the prevalence of bleeding disorders in women with menorrhagia.  Obstet Gynecol. 2005;  105 61-66
    CrossrefPubMedGoogle Scholar
  • 18 American College of Obstetricians and Gynecologists Committee Opinion No 263 . von Willebrand's disease in gynecologic practice.  Obstet Gynecol. 2001;  98 1185-1186
    CrossrefPubMedGoogle Scholar
  • 19 Dilley A, Drews C, Lally C, Austin H, Barnhart E, Evatt B. A survey of gynecologists concerning menorrhagia: perceptions of bleeding disorders as a possible cause.  J Womens Health Gend Based Med. 2002;  11 39-44
    CrossrefPubMedGoogle Scholar
  • 20 Chi C, Shiltagh N, Kingman C EC, Economides D L, Lee C A, Kadir R A. Identification and management of women with inherited bleeding disorders: a survey of obstetricians and gynaecologists in the United Kingdom.  Haemophilia. 2006;  12 405-412
    CrossrefPubMedGoogle Scholar
  • 21 Kadir R A, Economides D L, Sabin C A, Owens D, Lee C A. Frequency of inherited bleeding disorders in women with menorrhagia.  Lancet. 1998;  351 485-489
    CrossrefPubMedGoogle Scholar
  • 22 Quiroga T, Goycoolea M, Munoz B et al.. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients.  J Thromb Haemost. 2004;  2 892-898
    CrossrefPubMedGoogle Scholar
  • 23 James A H, Lukes A S, Brancazio L R, Thames E, Ortel T L. Use of a new platelet function analyzer to detect von Willebrand disease in women with menorrhagia.  Am J Obstet Gynecol. 2004;  191 449-455
    CrossrefPubMedGoogle Scholar
  • 24 Kouides P A, Conard J, Peyvandi F, Lukes A, Kadir R. Hemostasis and menstruation: appropriate investigation for underlying disorders of hemostasis in women with excessive menstrual bleeding.  Fertil Steril. 2005;  84 1345-1351
    CrossrefPubMedGoogle Scholar
  • 25 Rodeghiero F, Castaman G, Tosetto A et al.. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study.  J Thromb Haemost. 2005;  3 2619-2626
    CrossrefPubMedGoogle Scholar
  • 26 Fraser I S, McCarron G, Markham R. A preliminary study of factors influencing perception of menstrual blood loss volume.  Am J Obstet Gynecol. 1984;  149 788-793
    PubMedGoogle Scholar
  • 27 Chimbira T H, Anderson A BM, Turnbull A C. Relation between measured menstrual blood loss and patient's subjective assessment of loss, duration of bleeding, number of sanitary towels used, uterine weight and endometrial surface area.  Br J Obstet Gynaecol. 1980;  87 603-609
    PubMedGoogle Scholar
  • 28 Hallberg L, Hogdahl A M, Nilsson L, Rybo G. Menstrual blood loss-a population study. Variation at different ages and attempts to define normality.  Acta Obstet Gynecol Scand. 1966;  45 320-351
    CrossrefPubMedGoogle Scholar
  • 29 Hallberg L, Nilsson L. Determination of menstrual blood loss.  Scand J Clin Lab Invest. 1964;  16 244-248
    PubMedGoogle Scholar
  • 30 Warner P E, Critchley H O, Lumsden M A, Campbell-Brown M, Douglas A, Murray G D. Menorrhagia II: is the 80-mL blood loss criterion useful in management of complaint of menorrhagia?.  Am J Obstet Gynecol. 2004;  190 1224-1229
    CrossrefPubMedGoogle Scholar
  • 31 Warner P E, Critchley H O, Lumsden M A, Campbell-Brown M, Douglas A, Murray G D. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods: a survey with follow-up data.  Am J Obstet Gynecol. 2004;  190 1216-1223
    CrossrefPubMedGoogle Scholar
  • 32 Higham J M, O'Brien P M, Shaw R W. Assessment of menstrual blood loss using a pictorial chart.  Br J Obstet Gynaecol. 1990;  97 734-739
    CrossrefPubMedGoogle Scholar
  • 33 Janssen C A, Scholten P C, Heintz A P. A simple visual assessment technique to discriminate between menorrhagia and normal menstrual blood loss.  Obstet Gynecol. 1995;  85 977-982
    CrossrefPubMedGoogle Scholar
  • 34 Kirtava A, Crudder S, Dilley A, Lally C, Evatt B. Trends in clinical management of women with von Willebrand disease: a survey of 75 women enrolled in haemophilia treatment centres in the United States.  Haemophilia. 2004;  10 158-161
    CrossrefPubMedGoogle Scholar
  • 35 Kadir R A, Economides D L, Sabin C A, Owens D, Lee C A. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive.  Thromb Haemost. 1999;  82 1456-1461
    Article in Thieme ConnectPubMedGoogle Scholar
  • 36 Miller C H, Dilley A, Richardson L, Hooper W C, Evatt L. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women.  Am J Hematol. 2001;  67 125-129
    CrossrefPubMedGoogle Scholar
  • 37 Sukhu K, Poovalingam V, Mahomed R, Giangrande P LF. Ethnic variation in von Willebrand factor levels can influence the diagnosis of von Willebrand disease.  Clin Lab Haematol. 2003;  25 247-249
    PubMedGoogle Scholar
  • 38 Dilley A, Drews C, Miller C et al.. von Willebrand disease and other inherited bleeding disorders in women with diagnosed menorrhagia.  Obstet Gynecol. 2001;  97 630-636
    CrossrefPubMedGoogle Scholar
  • 39 Gill J C, Endres-Brooks J, Bauer P J, Marks W J, Montgomery R R. The effect of ABO blood group on the diagnosis of von Willebrand disease.  Blood. 1987;  69 1691-1695
    CrossrefPubMedGoogle Scholar
  • 40 Nitu-Whalley I C, Lee C A, Griffioen A, Jenkins P V, Pasi K J. Type 1 von Willebrand disease-a clinical retrospective study of the diagnosis, the influence of the ABO blood group and the role of the bleeding history.  Br J Haematol. 2000;  108 259-264
    CrossrefPubMedGoogle Scholar
  • 41 Bauduer F, Ducout L. Is the assessment of von Willebrand disease prevalence an achievable challenge? The example of the French Basque Country where blood group O and factor XI deficiency are highly prevalent.  J Thromb Haemost. 2004;  2 1724-1726
    CrossrefPubMedGoogle Scholar
  • 42 Sadler J E. Slippery criteria for von Willebrand disease type 1.  J Thromb Haemost. 2004;  2 1720-1723
    CrossrefPubMedGoogle Scholar
  • 43 Blombäck M, Eneroth P, Andersson O, Anvret M. On laboratory problems in diagnosing mild von Willebrand's disease.  Am J Hematol. 1992;  40 117-120
    CrossrefPubMedGoogle Scholar
  • 44 Mandalaki T, Louizou C, Dimitriadou C, Symeonidis P. Variations in factor VIII during the menstrual cycle in normal women.  N Engl J Med. 1980;  302 1093-1094
    PubMedGoogle Scholar
  • 45 Miller C H, Dilley A B, Drews C, Richardson L, Evatt B. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle.  Thromb Haemost. 2002;  87 1082-1083
    PubMedGoogle Scholar
  • 46 Onundarson P T. Treatment of menorrhagia in von Willebrand's disease.  Haemophilia. 1999;  5 76
    CrossrefPubMedGoogle Scholar
  • 47 Beller F K, Ebert C. Effects of oral contraceptives on blood coagulation. A review.  Obstet Gynecol Surv. 1985;  40 425-436
    PubMedGoogle Scholar
  • 48 Prasad R N, Koh S C, Viegas O A, Ratnam S S. Effects on haemostasis after two year use of low dose combined oral contraceptive with gestodene or levonorgestrol.  Clin Appl Thromb Hemost. 1998;  5 60-70
    PubMedGoogle Scholar
  • 49 Harris G M, Stendt C L, Vollenhoven B J, Gan T E, Tipping P G. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.  Am J Hematol. 1999;  60 175-180
    CrossrefPubMedGoogle Scholar
  • 50 Royal College of Obstetricians and Gynaecologists .The Initial Management of Menorrhagia-National Evidence-Based Clinical Guidelines. London; RCOG Press 1998
    Google Scholar
  • 51 Royal College of Obstetricians and Gynaecologists .The Management of Menorrhagia in Secondary Care-National Evidence-Based Clinical Guidelines. London; RCOG Press 1999
    Google Scholar
  • 52 Kadir R A, Lukes A S, Kouides P A, Fernandez H, Goudemand J. Management of excessive menstrual bleeding in women with hemostatic disorders.  Fertil Steril. 2005;  84 1352-1359
    CrossrefPubMedGoogle Scholar
  • 53 Wellington K, Wagstaff A J. Tranexamic acid: a review of its use in the management of menorrhagia.  Drugs. 2003;  63 1417-1433
    CrossrefPubMedGoogle Scholar
  • 54 Bonnar J, Sheppard B L. Treatment of menorrhagia during menstruation: randomised controlled trial of ethamsylate, mefenamic acid, and tranexamic acid.  BMJ. 1996;  313 579-582
    PubMedGoogle Scholar
  • 55 Milsom I, Andersson K, Andersch B, Rybo G. A comparison of flurbiprofen, tranexamic acid, and a levonorgestrel-releasing intrauterine contraceptive device in the treatment of idiopathic menorrhagia.  Am J Obstet Gynecol. 1991;  164 879-883
    PubMedGoogle Scholar
  • 56 British Medical Association and the Royal Pharmaceutical Society of Great Britain .British National Formulary. London; British Medical Association and the Royal Pharmaceutical Society of Great Britain 2004
    Google Scholar
  • 57 Ong Y L, Hull D R, Mayne E E. Menorrhagia in von Willebrand disease successfully treated with single daily dose tranexamic acid.  Haemophilia. 1998;  4 63-65
    CrossrefPubMedGoogle Scholar
  • 58 Rybo G. Tranexamic acid therapy: effective treatment in heavy menstrual bleeding: clinical update on safety.  Therapeutic Advances. 1991;  4 1-8
    PubMedGoogle Scholar
  • 59 Callard G V, Litofsky F S, DeMerre L J. Menstruation in women with normal or artificially controlled cycles.  Fertil Steril. 1966;  17 684-688
    PubMedGoogle Scholar
  • 60 Ramcharan S, Pellegrin F A, Ray R M, Hsu J P. The Walnut Creek Contraceptive Drug Study. A prospective study of the side effects of oral contraceptives. Volume III, an interim report: a comparison of disease occurrence leading to hospitalization or death in users and nonusers of oral contraceptives.  J Reprod Med. 1980;  25 345-372
    PubMedGoogle Scholar
  • 61 Nilsson L, Rybo G. Treatment of menorrhagia.  Am J Obstet Gynecol. 1971;  110 713-720
    PubMedGoogle Scholar
  • 62 Fraser I S, McCarron G. Randomized trial of 2 hormonal and 2 prostaglandin-inhibiting agents in women with a complaint of menorrhagia.  Aust N Z J Obstet Gynaecol. 1991;  31 66-70
    CrossrefPubMedGoogle Scholar
  • 63 Foster P A. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH.  Thromb Haemost. 1995;  74 784-790
    PubMedGoogle Scholar
  • 64 Sulak P J, Cressman B E, Waldrop E, Holleman S, Kuehl T J. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms.  Obstet Gynecol. 1997;  89 179-183
    CrossrefPubMedGoogle Scholar
  • 65 Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani P G. Cyproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis.  Fertil Steril. 2002;  77 52-61
    CrossrefPubMedGoogle Scholar
  • 66 Miller L, Notter K M. Menstrual reduction with extended use of combination oral contraceptive pills: randomized controlled trial.  Obstet Gynecol. 2001;  98 771-778
    CrossrefPubMedGoogle Scholar
  • 67 Edelman A B, Gallo M F, Jensen J T, Nichols M D, Schulz K F, Grimes D A. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception.  Cochrane Database Syst Rev. 2005;  CD004695
    PubMedGoogle Scholar
  • 68 Lethagen S, Harris A S, Sjorin E, Nilsson I M. Intranasal and intravenous administration of desmopressin: effect on F VIII/vWF, pharmacokinetics and reproducibility.  Thromb Haemost. 1987;  58 1033-1036
    PubMedGoogle Scholar
  • 69 Mannucci P M, Aberg M, Nilsson I M, Robertson B. Mechanism of plasminogen activator and factor VIII increase after vasoactive drugs.  Br J Haematol. 1975;  30 81-93
    CrossrefPubMedGoogle Scholar
  • 70 Edlund M, Blombäck M, He S. On the correlation between local fibrinolytic activity in menstrual fluid and total blood loss during menstruation and effects of desmopressin.  Blood Coagul Fibrinolysis. 2003;  14 593-598
    PubMedGoogle Scholar
  • 71 Rodeghiero F, Castaman G, Mannucci P M. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A.  Thromb Haemost. 1996;  76 692-696
    PubMedGoogle Scholar
  • 72 Leissinger C, Becton D, Cornell Jr C, Cox G J. High-dose DDAVP intranasal spray (Stimate) for the prevention and treatment of bleeding in patients with mild haemophilia A, mild or moderate type 1 von Willebrand disease and symptomatic carriers of haemophilia A.  Haemophilia. 2001;  7 258-266
    CrossrefPubMedGoogle Scholar
  • 73 Kadir R A, Lee C A, Sabin C A, Pollard D, Economides D L. DDAVP nasal spray for treatment of menorrhagia in women with inherited bleeding disorders: a randomized placebo-controlled crossover study.  Haemophilia. 2002;  8 787-793
    CrossrefPubMedGoogle Scholar
  • 74 Edlund M, Blombäck M, Fried G. Desmopressin in the treatment of menorrhagia in women with no common coagulation factor deficiency but with prolonged bleeding time.  Blood Coagul Fibrinolysis. 2002;  13 225-231
    CrossrefPubMedGoogle Scholar
  • 75 Haynes P J, Hodgson H, Anderson A B, Turnbull A C. Measurement of menstrual blood loss in patients complaining of menorrhagia.  Br J Obstet Gynaecol. 1977;  84 763-768
    PubMedGoogle Scholar
  • 76 Coulter A, Kelland J, Peto V, Rees M C. Treating menorrhagia in primary care. An overview of drug trials and a survey of prescribing practice.  Int J Technol Assess Health Care. 1995;  11 456-471
    CrossrefPubMedGoogle Scholar
  • 77 Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding.  Cochrane Database Syst Rev. 2000;  CD001016
    PubMedGoogle Scholar
  • 78 Irvine G A, Campbell-Brown M B, Lumsden M A, Heikkila A, Walker J J, Cameron I T. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia.  Br J Obstet Gynaecol. 1998;  105 592-598
    PubMedGoogle Scholar
  • 79 Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding.  Cochrane Database Syst Rev. 2000;  CD000400
    PubMedGoogle Scholar
  • 80 Silverberg S G, Haukkamaa M, Arko H, Nilsson C G, Luukkainen T. Endometrial morphology during long-term use of levonorgestrel-releasing intrauterine devices.  Int J Gynecol Pathol. 1986;  5 235-241
    PubMedGoogle Scholar
  • 81 Stewart A, Cummins C, Gold L, Jordan R, Phillips W. The effectiveness of the levonorgestrel-releasing intrauterine system in menorrhagia: a systematic review.  BJOG. 2001;  108 74-86
    CrossrefPubMedGoogle Scholar
  • 82 Lahteenmaki P, Haukkamaa M, Puolakka J et al.. Open randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy.  BMJ. 1998;  316 1122-1126
    CrossrefPubMedGoogle Scholar
  • 83 Hidalgo M, Bahamondes L, Perrotti M, Diaz J, Dantas-Monteiro C, Petta C. Bleeding patterns and clinical performance of the levonorgestrel-releasing intrauterine system (Mirena) up to two years.  Contraception. 2002;  65 129-132
    CrossrefPubMedGoogle Scholar
  • 84 Andersson K, Odlind V, Rybo G. Levonorgestrel-releasing and copper-releasing (Nova T) IUDs during five years of use: a randomized comparative trial.  Contraception. 1994;  49 56-72
    CrossrefPubMedGoogle Scholar
  • 85 Sivin I, el Mahgoub S, McCarthy T et al.. Long-term contraception with the levonorgestrel 20 mcg/day (LNg 20) and the copper T 380Ag intrauterine devices: a five-year randomized study.  Contraception. 1990;  42 361-378
    CrossrefPubMedGoogle Scholar
  • 86 Xiao B, Wu S C, Chong J, Zeng T, Han L H, Luukkainen T. Therapeutic effects of the levonorgestrel-releasing intrauterine system in the treatment of idiopathic menorrhagia.  Fertil Steril. 2003;  79 963-969
    CrossrefPubMedGoogle Scholar
  • 87 Kingman C E, Kadir R A, Lee C A, Economides D L. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders.  BJOG. 2004;  111 1425-1428
    CrossrefPubMedGoogle Scholar
  • 88 Schaedel Z E, Dolan G, Powell M. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders.  Am J Obstet Gynecol. 2005;  193 1361-1363
    CrossrefPubMedGoogle Scholar
  • 89 Lethaby A, Shepperd S, Cooke I, Farquhar C. Endometrial resection and ablation versus hysterectomy for heavy menstrual bleeding.  Cochrane Database Syst Rev. 2000;  CD000329
    PubMedGoogle Scholar
  • 90 Lethaby A, Hickey M. Endometrial destruction techniques for heavy menstrual bleeding: a Cochrane review.  Hum Reprod. 2002;  17 2795-2806
    CrossrefPubMedGoogle Scholar
  • 91 Maresh M J, Metcalfe M A, McPherson K et al.. The VALUE national hysterectomy study: description of the patients and their surgery.  BJOG. 2002;  109 302-312
    PubMedGoogle Scholar
  • 92 McPherson K, Metcalfe M A, Herbert A et al.. Severe complications of hysterectomy: the VALUE study.  BJOG. 2004;  111 688-694
    PubMedGoogle Scholar

 Dr.
R.A. Kadir

Department of Obstetrics and Gynaecology, Royal Free Hospital

Pond Street, London NW3 2QG, United Kingdom

Email: rezan.abdul-kadir@royalfree.nhs.uk

      >